Carbamic Acid

Carbamic Acid

SCHEMBL1421167

NC(=O)O.NCCNCCNCCNCCNCCN

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.65
CA6 P23280 5/20 0.65
CA7 P43166 5/20 0.65
CA9 Q16790 5/20 0.65
CA14 Q9ULX7 5/20 0.65
CA5B Q9Y2D0 5/20 0.65
LMNA P02545 4/20 0.65
CA2 P00918 4/20 0.65
CA4 P22748 4/20 0.65
CA5A P35218 4/20 0.65
CA3 P07451 3/20 0.65
ALOX15 P16050 3/20 0.65
TDP1 Q9NUW8 2/20 0.65
CA1 P00915 2/20 0.65
ALDH1A1 P00352 1/20 0.65
TP53 P04637 1/20 0.65
KDM4E B2RXH2 1/20 0.61
KMT2A Q03164 3/20 0.59
MEN1 O00255 2/20 0.59
RECQL P46063 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carbamic Acid SCHEMBL10380516 0.97 CA12 (0.62) CA12CA6CA7CA9CA14
Carbamic Acid SCHEMBL9296897 0.94 CA12 (0.59) CA12CA6CA7CA9CA14
Trientine SCHEMBL6058519 0.92 MAOA (0.56) CA12CA6CA7CA9CA14
Trientine SCHEMBL20639324 0.91 CA12 (0.69) CA12CA6CA7CA9CA14
Bicarbonate SCHEMBL10634656 0.91 CA12 (0.69) CA12CA6CA7CA9CA14
Bicarbonate SCHEMBL2443699 0.88 CA12 (0.67) CA12CA6CA7CA9CA14
Urea SCHEMBL1662263 0.88 CA12 (0.67) CA12CA6CA7CA9CA14
Carbamic Acid SCHEMBL1246708 0.87 CA12 (0.50) CA12CA6CA7CA9CA14
Trientine SCHEMBL10875300 0.86 CA12 (0.61) CA12CA6CA7CA9CA14
Trientine SCHEMBL159616 0.86 CA12 (0.61) CA12CA6CA7CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374508-A1 Compositions and Methods Targeting circ2082 for the Treatment of Cancer NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-11-23 US disclosed
EP-4229202-A1 COMPOSITIONS AND METHODS TARGETING CIRC2082 FOR THE TREATMENT OF CANCER The Brigham & Women's Hospital, Inc. (US) 2023-08-23 EP disclosed
WO-2022081693-A1 COMPOSITIONS AND METHODS TARGETING CIRC2082 FOR THE TREATMENT OF CANCER THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2022-04-21 WO disclosed
US-9682098-B2 Compounds suited as nanocarriers for active agents and their use RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2017-06-20 US disclosed
US-20160145628-A1 NANOCARRIER SYSTEM FOR MICRORNAS AND USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2016-05-26 US disclosed
US-20150320786-A1 COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE FREIE UNIVERSITAET BERLIN (DE) 2015-11-12 US disclosed
US-9102595-B2 Compounds suited as nanocarriers for active agents and their use RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2015-08-11 US disclosed
WO-2014203189-A1 NANOCARRIER SYSTEM FOR MICRORNAS AND USES THEREOF ROSETTA GENOMICS LTD. (IL) 2014-12-24 WO disclosed
EP-2296707-B1 COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE FREIE UNIVERSITÄT BERLIN (DE) 2014-11-12 EP disclosed
US-20110082090-A1 COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2011-04-07 US disclosed
EP-2296707-A2 COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE Freie Universität Berlin (DE) 2011-03-23 EP disclosed
WO-2009141170-A2 COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE FREIE UNIVERSITÄT BERLIN (DE) 2009-11-26 WO disclosed
EP-2123304-A1 Compounds suited as nanocarriers for active agents and their use Freie Universität Berlin (DE) 2009-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150320786-A1 COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE KIT, ABCB1, BCOR CA12 3392/4885CA6 2407/4885CA7 2648/4885
US-20110082090-A1 COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE KIT, ABCB1, BCOR CA12 3392/4885CA6 2407/4885CA7 2648/4885
US-20160145628-A1 NANOCARRIER SYSTEM FOR MICRORNAS AND USES THEREOF MKI67, ELAVL1, ELAVL3 CA12 3798/4885CA6 4154/4885CA7 4452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.